First Time Loading...
V

VIVA Biotech Holdings
HKEX:1873

Watchlist Manager
VIVA Biotech Holdings
HKEX:1873
Watchlist
Price: 0.6 HKD -1.64%
Updated: May 3, 2024

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
VIVA Biotech Holdings

Revenue
2.2B CNY
Cost of Revenue
-1.4B CNY
Gross Profit
738.4m CNY
Operating Expenses
-527.4m CNY
Operating Income
211.1m CNY
Other Expenses
-327.2m CNY
Net Income
-116.1m CNY

Margins Comparison
VIVA Biotech Holdings Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
VIVA Biotech Holdings
HKEX:1873
1.3B HKD
34%
10%
-5%
US
Thermo Fisher Scientific Inc
NYSE:TMO
220.9B USD
40%
17%
14%
US
Danaher Corp
NYSE:DHR
182.8B USD
58%
22%
18%
CH
Lonza Group AG
SIX:LONN
37.1B CHF
36%
20%
10%
KR
Samsung Biologics Co Ltd
KRX:207940
55.2T KRW
49%
30%
23%
US
IQVIA Holdings Inc
NYSE:IQV
40.3B USD
35%
14%
9%
US
Agilent Technologies Inc
NYSE:A
40.3B USD
51%
19%
18%
US
Mettler-Toledo International Inc
NYSE:MTD
26.9B USD
59%
29%
21%
US
West Pharmaceutical Services Inc
NYSE:WST
26.9B USD
37%
23%
19%
IE
ICON PLC
NASDAQ:ICLR
24.9B USD
30%
13%
8%
FR
Sartorius Stedim Biotech SA
PAR:DIM
19B EUR
43%
15%
9%
Country CN
Market Cap 1.3B HKD
Gross Margin
34%
Operating Margin
10%
Net Margin
-5%
Country US
Market Cap 220.9B USD
Gross Margin
40%
Operating Margin
17%
Net Margin
14%
Country US
Market Cap 182.8B USD
Gross Margin
58%
Operating Margin
22%
Net Margin
18%
Country CH
Market Cap 37.1B CHF
Gross Margin
36%
Operating Margin
20%
Net Margin
10%
Country KR
Market Cap 55.2T KRW
Gross Margin
49%
Operating Margin
30%
Net Margin
23%
Country US
Market Cap 40.3B USD
Gross Margin
35%
Operating Margin
14%
Net Margin
9%
Country US
Market Cap 40.3B USD
Gross Margin
51%
Operating Margin
19%
Net Margin
18%
Country US
Market Cap 26.9B USD
Gross Margin
59%
Operating Margin
29%
Net Margin
21%
Country US
Market Cap 26.9B USD
Gross Margin
37%
Operating Margin
23%
Net Margin
19%
Country IE
Market Cap 24.9B USD
Gross Margin
30%
Operating Margin
13%
Net Margin
8%
Country FR
Market Cap 19B EUR
Gross Margin
43%
Operating Margin
15%
Net Margin
9%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
VIVA Biotech Holdings Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
VIVA Biotech Holdings
HKEX:1873
1.3B HKD
-3%
-2%
4%
6%
US
Thermo Fisher Scientific Inc
NYSE:TMO
220.9B USD
13%
6%
9%
8%
US
Danaher Corp
NYSE:DHR
182.8B USD
16%
10%
12%
10%
CH
Lonza Group AG
SIX:LONN
37.1B CHF
7%
4%
9%
8%
KR
Samsung Biologics Co Ltd
KRX:207940
55.2T KRW
9%
5%
9%
6%
US
IQVIA Holdings Inc
NYSE:IQV
40.3B USD
23%
5%
10%
9%
US
Agilent Technologies Inc
NYSE:A
40.3B USD
21%
11%
14%
14%
US
Mettler-Toledo International Inc
NYSE:MTD
26.9B USD
-1 261%
23%
48%
28%
US
West Pharmaceutical Services Inc
NYSE:WST
26.9B USD
21%
16%
22%
20%
IE
ICON PLC
NASDAQ:ICLR
24.9B USD
8%
4%
8%
6%
FR
Sartorius Stedim Biotech SA
PAR:DIM
19B EUR
8%
4%
7%
5%
Country CN
Market Cap 1.3B HKD
ROE
-3%
ROA
-2%
ROCE
4%
ROIC
6%
Country US
Market Cap 220.9B USD
ROE
13%
ROA
6%
ROCE
9%
ROIC
8%
Country US
Market Cap 182.8B USD
ROE
16%
ROA
10%
ROCE
12%
ROIC
10%
Country CH
Market Cap 37.1B CHF
ROE
7%
ROA
4%
ROCE
9%
ROIC
8%
Country KR
Market Cap 55.2T KRW
ROE
9%
ROA
5%
ROCE
9%
ROIC
6%
Country US
Market Cap 40.3B USD
ROE
23%
ROA
5%
ROCE
10%
ROIC
9%
Country US
Market Cap 40.3B USD
ROE
21%
ROA
11%
ROCE
14%
ROIC
14%
Country US
Market Cap 26.9B USD
ROE
-1 261%
ROA
23%
ROCE
48%
ROIC
28%
Country US
Market Cap 26.9B USD
ROE
21%
ROA
16%
ROCE
22%
ROIC
20%
Country IE
Market Cap 24.9B USD
ROE
8%
ROA
4%
ROCE
8%
ROIC
6%
Country FR
Market Cap 19B EUR
ROE
8%
ROA
4%
ROCE
7%
ROIC
5%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More